Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes. - Wikidata - wikimedia - TriplyDB

Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.

Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.

http://www.wikidata.org/entity/Q33690357

about

Lipids, blood pressure and kidney update 2015 Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin.ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population

P2860

Q26771550-56B0030E-878A-4DFC-8894-D7B603E3E5FF Q30490270-6017C56A-1A9A-48CB-93E4-4C15811B471B Q35799847-3BE1726C-815E-41D6-932B-8A9B31EAABD8 Q39514336-4AB195ED-2206-45E9-B63D-DA7135F6B724

P2860

Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.

http://www.wikidata.org/entity/Q33690357

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.

@ast

Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.

@en

type

label

Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.

@ast

Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.

@en

prefLabel

Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.

@ast

Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.

@en

P1433

Q33690357-36F47682-87AA-43AF-BC6F-3E77FC1499C9

P1476

Q33690357-E89439DD-3361-4AFF-B499-A6565482F762

P2093

Q33690357-0643E767-A610-4B97-B37A-BD0660E57225

Q33690357-22AF15F2-D4F8-4A79-8716-402B06CCD124

Q33690357-26351817-C418-4F16-AD1F-D337739D1661

Q33690357-798E66EF-ABAB-4B6A-A0D3-3EDC0413FDA6

Q33690357-AF5F7FE7-FBEB-43E6-BC3F-B990DC1FC362

Q33690357-E303846C-23B9-4A0F-B0F8-9C851B893F5F

P2860

Q33690357-166E48FC-F71F-48FE-B0AB-EFB401B09E50

Q33690357-1AEEC206-61C6-439C-BE89-8DF954FA14AD

Q33690357-1B3D3822-112B-4E09-BB00-2698089A04E5

Q33690357-225B90EE-09E7-47E7-A52A-0F3D0639ACA6

Q33690357-250B4A81-7DF0-4783-A4F1-AE9531597556

Q33690357-25BB6B32-7B3B-4DCE-BA80-B95D35925C63

Q33690357-318860CB-B918-42CD-AC6F-715C0EC6A89D

Q33690357-469A79B1-5F54-40FB-9FEE-D8F454DF5113

Q33690357-547799E4-BC47-4D37-9E8E-FBC7E5899B35

Q33690357-653A8594-1DBC-4DD2-9CF4-A06D720F5864

P304

Q33690357-53FAB1D9-8672-45C6-B145-9D86260A2ABA

P31

Q33690357-F43AC2C7-77B3-4E1F-B22E-317315CE4AA6

P433

Q33690357-832C7FF1-C76C-4A21-9000-92F16933C369

P478

Q33690357-CEE75B7F-D3CF-41EF-81FF-DC66C6053E14

P577

Q33690357-64188DEA-5EE4-45E8-B85F-E95440E6F996

P698

Q33690357-2291C48C-D478-4132-A87F-24CC79C29C1A

P921

Q33690357-42839EA4-B949-4118-A89B-C7D8813C7DEA

Q33690357-9502D7FF-3350-48D8-8B50-3DA5DECBA4B7

P932

Q33690357-F20D69A2-1277-4227-8D47-C88F8BDC93A9

P1433

Discovery Medicine

P1476

Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes.

@en

P2093

Adam M Suhy

http://www.w3.org/2001/XMLSchema#string

Damiano Baldassarre

http://www.w3.org/2001/XMLSchema#string

Joseph P Kitzmiller

http://www.w3.org/2001/XMLSchema#string

Katherine Hartmann

http://www.w3.org/2001/XMLSchema#string

Philip F Binkley

http://www.w3.org/2001/XMLSchema#string

Saurabh R Pandey

http://www.w3.org/2001/XMLSchema#string

P2860

Newly identified loci that influence lipid concentrations and risk of coronary artery disease

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk

SLCO1B1 variants and statin-induced myopathy--a genomewide study

Growing epidemic of coronary heart disease in low- and middle-income countries

The use of phenome-wide association studies (PheWAS) for exploration of novel genotype-phenotype relationships and pleiotropy discovery.

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy

Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study

Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.

P304

45-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

86

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23911231

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

P932

4039562

http://www.w3.org/2001/XMLSchema#string